The Clinical Research Unit of the Macula Research Group have completed the following clinical trials:
The HAWK study is a 2 year study to evaluate the efficacy and safety of study medication versus Aflibercept in subjects with neovascular age-related macular degeneration. Patient will be enrolled into one of three arms, Study Dose A (3mg), Study Dose B (6mg) or Aflibercept, and will receive this treatment intravitreally (injection into the eye).
A two year trial studying the new onset of a type of dry macular degeneration called geographic atrophy in patients with (wet) age-related macular degeneration while they are receiving their standard of care treatment of ranibizumab (Lucentis) or aflibercept (Eylea). Eligible eyes must be treatment naïve, ie not previously had injections of Lucentis or Eylea (or other similar medications in the eye) prior to commencing the study.
Persistent swelling despite treatment with bevacizumab (Avastin) or dexamethasone implants (Ozurdex) occurs in some patients. This study assigns the opposite treatment to the one previously received. Therefore, eyes previously treated with Avastin will receive Ozurdex and eyes previously treated with Ozurdex will receive Avastin over a period of 6 months as needed. The study aims to assess whether the switch in treatments is beneficial.
This is a non therapeutic NHMRC funded trial attempting to identify the genes contributing to diabetic retinopathy in Type I and Type II diabetics.
This international study of a Ciliary Neurotropic Factor (CNTF) implant in the eye is an international study and the first treatment study in Australia for Macular Telangiectasia. Patients must first be enrolled in the MacTel (Natural History) Study above.
to Save Sight Institute’s mailing list for news and updates